Full-Time

Clinical Engagement Lead

West / Midwest

Updated on 9/3/2026

Beeline Medicines

Beeline Medicines

51-200 employees

Clinical-stage biotech developing precision autoimmune therapies

Compensation Overview

$180k - $235k/yr

+ Annual bonus + Long-term incentive award + Equity

United States

In Person

Field-based within the assigned multi-state territory; travel of 50% or more may be required, including occasional overnight stays. Territory assignments may change.

Bachelor's, Master's

Category
Biology & Biotech (1)
Required Skills
FDA Regulations
Data Analysis

Get referred to Beeline Medicines

See people who can refer or advise you

Requirements
  • A bachelor's degree in a scientific or related discipline is required.
  • At least 8 years of experience in clinical development, clinical research, clinical operations, or a field-based clinical engagement role within the pharmaceutical or biotechnology industry is required.
  • Demonstrated experience managing investigator relationships and supporting clinical trial site activation and enrollment is required.
  • Experience collaborating with contract research organizations, investigative sites, and field medical teams, including Medical Science Liaison partnerships, is required.
  • Strong scientific and clinical knowledge of immunology and inflammation is required, including disease biology, standard of care, clinical trial design considerations, and the competitive clinical research landscape across relevant indications.
  • Expertise in clinical trial site management and investigator engagement is required, including site feasibility assessment, investigator identification and qualification, site initiation support, and enrollment optimization strategies.
  • Working knowledge of Good Clinical Practice requirements, International Council for Harmonisation guidelines, and Food and Drug Administration regulations governing investigator interactions, clinical site oversight, and field-based clinical development activities is required.
  • Ability to safely and successfully operate a motor vehicle is required, along with a valid United States driver's license and a driving record compliant with company standards.
  • The ability to manage a multi-state territory with a diverse customer base is required, depending on geography.
  • The ability to work evenings and weekends as needed for physician or patient events, both in person and virtually, is required.
  • The ability to travel 50% or more as needed, including occasional overnight stays, is required.
Responsibilities
  • Build and manage a portfolio of investigator and clinical site relationships in the immunology and inflammation therapeutic area.
  • Lead site identification and feasibility activities for clinical trials by conducting operational site assessments, evaluating investigator interest and patient population access, and providing strategic recommendations on site selection and activation.
  • Serve as the primary clinical liaison to regional and country-level investigators by facilitating peer-to-peer scientific exchange, conducting protocol discussions, supporting site initiation and training, and maintaining investigator engagement throughout the trial lifecycle.
  • Support clinical trial enrollment and retention at regional and country sites by identifying enrollment challenges, implementing site-level solutions, and maintaining site motivation and engagement.
  • Capture and communicate clinical landscape intelligence, including investigator perspectives, competitive trial activity, site capacity trends, and unmet medical need insights, to Clinical Development, Medical Affairs, and Commercial teams.
  • Partner with Medical Affairs Medical Science Liaisons to coordinate and align investigator-level scientific engagement activities and maintain boundaries between clinical trial support and medical affairs activities.
  • Represent the organization at clinical and scientific meetings, investigator symposia, disease-area conferences, and site visits.
  • Develop and implement site engagement strategies to improve study start-up, enrollment performance, retention, and site satisfaction.
  • Partner with investigators, study coordinators, and site staff to support patient identification and recruitment efforts.
  • Provide operational guidance and best practices to sites related to diverse patient enrollment and community engagement.
  • Conduct regular field engagement with investigative sites and community stakeholders to strengthen study execution and recruitment performance.
  • Monitor enrollment trends, site performance metrics, and patient engagement effectiveness using data-driven approaches.
  • Identify enrollment risks proactively and implement mitigation and recovery plans.
  • Perform other duties and responsibilities as assigned.
Desired Qualifications
  • An advanced degree, such as an MS or MPH, in a relevant clinical, biomedical, or pharmaceutical sciences discipline is preferred.
  • Experience in immunology, inflammation, or a related therapeutic area is strongly preferred.

Beeline Medicines is a clinical-stage biotechnology company focused on precision therapies for autoimmune and inflammatory diseases, formed after in-licensing five programs from Bristol Myers Squibb with a $300 million Series A led by Bain Capital. Its lead programs include afimetoran, an oral lupus therapy that inhibits TLR7 and TLR8, lomedeucitinib, an allosteric TYK2 inhibitor, and two IND-stage biologics targeting IL-18 and IL-10 pathways. The drugs work by modulating specific immune signaling pathways to reduce inflammation, with afimetoran designed to address lupus drivers. The company differentiates itself by using in-licensed assets from a major pharma partner and combining them with an experienced leadership team to push multiple programs toward pivotal trials, starting with Phase 2 for afimetoran targeted for late 2026.

Company Size

51-200

Company Stage

Series A

Total Funding

$426.3M

Headquarters

Stamford, Connecticut

Founded

2025

Get referred to Beeline Medicines

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Beeline closed a $126.3 million extension on June 30, 2026, reaching $426.3 million.
  • FDA Fast Track for afimetoran in May 2025 accelerates regulatory interaction.
  • Management plans several clinical starts within 12 months, expanding catalysts beyond lupus.

What critics are saying

  • Afimetoran’s Phase 2 lupus readout in H2 2026 is the company’s make-or-break catalyst.
  • Failure versus Benlysta, Saphnelo, and competing lupus drugs kills the pivotal plan.
  • Five BMS-origin assets concentrate scientific risk; one bad readout can crush financing appetite.

What makes Beeline Medicines unique

  • BMS licensed five programs to Beeline in 2025, de-risking discovery.
  • Afimetoran targets TLR7/8, an upstream lupus mechanism unlike downstream cytokine biologics.
  • Saqib Islam and SpringWorks veterans bring repeatable biotech execution and exit experience.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Remote Work Options

Flexible Work Hours

Paid Vacation

Paid Holidays

Health Insurance

Company Equity

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-8%

1 year growth

-8%

2 year growth

-8%
Beeline Medicines
Jun 30th, 2026
Terms of Use - Beeline Medicines

Terms of Use Agreement Effective: April 8, 2026 1. Acceptance of the Terms and Conditions. Beeline Medicines Corporation (herein referred to as “Beeline,” “we,” “us” or “our”) provides and makes available this web site (the “Web Site”). All use of the Web Site is subject to the terms and conditions contained in this Terms of […]

Fierce Biotech
Jun 29th, 2026
BMS-backed Beeline raises $126M series A extension for autoimmune programs

Beeline Medicines has raised $126.3 million in a Series A extension, just two and a half months after emerging from stealth with $300 million in funding and five autoimmune programmes from Bristol Myers Squibb. The biotech startup, backed by BMS, is developing treatments targeting autoimmune diseases. The additional funding comes as the company rapidly advances its pipeline following its December debut. Details about the extension round's investors and the company's specific plans for the new capital were not disclosed.

Yahoo Finance
Apr 15th, 2026
Beeline debuts with $300M and immune drugs licensed from Bristol Myers

Beeline Medicines emerged from stealth with $300 million in Series A funding from Bain Capital to develop precision therapies for immune diseases. The company's pipeline includes five experimental medicines licensed from Bristol Myers Squibb nearly a year ago. Beeline's lead asset is afimetoran, a daily oral treatment for systemic lupus erythematosus targeting immune system receptors. A Phase 2 study is expected to complete in the second half of this year, with a pivotal programme planned thereafter. The pipeline also includes candidates for atopic dermatitis, lupus and plaque psoriasis, plus two preclinical assets. Saqib Islam, former CEO of SpringWorks Therapeutics, leads the company. Bain Capital previously backed Cerevel Therapeutics, acquired by AbbVie for nearly $9 billion, and Aiolos Bio, purchased by GSK.

Dealroom.co
Apr 15th, 2026
Beeline Medicines company information, funding & investors

Beeline Medicines, precision therapies for autoimmune and inflammatory diseases. Here you'll find information about their funding, investors and team.

GlobeNewswire
Apr 15th, 2026
Beeline Medicines Debuts to Deliver Category-Leading Precision Therapies for People Living with Autoimmune and Inflammatory Diseases

– Advancing a broad portfolio designed to deliver multiple paradigm-shifting therapies for devastating and underserved immune-mediated diseases –  – Lead...